KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Non Operating Income (2016 - 2025)

Emergent BioSolutions' Non Operating Income history spans 15 years, with the latest figure at -$22.8 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 25.97% year-over-year to -$22.8 million; the TTM value through Dec 2025 reached $24.8 million, up 350.51%, while the annual FY2025 figure was -$17.3 million, 49.42% up from the prior year.
  • Non Operating Income reached -$22.8 million in Q4 2025 per EBS's latest filing, down from -$3.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $77.9 million in Q3 2024 to a low of -$66.3 million in Q2 2024.
  • Average Non Operating Income over 5 years is -$2.0 million, with a median of -$8.6 million recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 827.27% in 2021, then skyrocketed 2150.0% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$9.9 million in 2021, then tumbled by 209.09% to -$30.6 million in 2022, then soared by 127.78% to $8.5 million in 2023, then crashed by 312.94% to -$18.1 million in 2024, then decreased by 25.97% to -$22.8 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Non Operating Income are -$22.8 million (Q4 2025), -$3.7 million (Q3 2025), and -$18.4 million (Q2 2025).